Intellia Therapeutics, Inc.

The Company expects that its cash, cash equivalents and marketable securities as of June 30, 2026 will enable the Company to fund its ongoing operating expenses and capital expenditure requirements for at least the twelve-month period following the issuance of these condensed consolidated financial statements.

SEC original ↗Intellia Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Treasury and other government-backed securities $ 220,790 $ 345 $ ( 18 ) $ 221,117 Financial institution debt securities 146,375 458 ( 18 ) 146,815 Corporate debt securities 81,478 266 ( 6 ) 81,738 Total $ 448,643 $ 1,069 $ ( 42 ) $ 449,670 The amortized cost of available-for-sale securities is adjusted for amortization of premiums and accretion of discounts to maturity.

SEC original ↗Intellia Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Treasury and other government-backed securities 275,645 184,124 91,521 - Financial institution debt securities 168,784 - 168,784 - Corporate debt securities 77,797 - 77,797 - Total marketable securities 522,226 184,124 338,102 - Investment in Kyverna Therapeutics, Inc.

SEC original ↗Intellia Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Treasury and other government-backed securities 221,117 150,852 70,265 - Financial institution debt securities 146,815 - 146,815 - Corporate debt securities 81,738 - 81,738 - Total marketable securities 449,670 150,852 298,818 - Investment in Kyverna Therapeutics, Inc.

SEC original ↗Intellia Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The 2025 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, RSAs, RSUs, unrestricted stock awards, cash-based awards and dividend equivalent rights.

SEC original ↗Intellia Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The Inducement Plan provides for the grant of non-qualified stock options, stock appreciation rights, RSAs, RSUs, unrestricted stock awards and dividend equivalent rights to individuals who are not employed by the Company.

SEC original ↗Intellia Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

(NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported operational highlights and financial results for the second quarter ended June 30, 2025.

SEC original ↗Intellia Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

The decrease in cash, cash equivalents and marketable securities includes approximately $65.0 million of non-recurring cash payments in the first half of 2025 associated with the Company’s previously announced portfolio prioritization, workforce reduction, and real estate consolidation.

SEC original ↗Intellia Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

(NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies.

SEC original ↗Intellia Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients.

SEC original ↗Intellia Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

( Intellia, or the Company ) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies.

SEC original ↗Intellia Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.

SEC original ↗Intellia Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q.

SEC original ↗Intellia Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Legal Proceedings 30 Item 1A.

SEC original ↗Intellia Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Commitments and Contingencies Litigation From time to time, the Company may be involved in legal and administrative proceedings and claims of various types.

SEC original ↗Intellia Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

On February 11, 2025, a purported stockholder of the Company filed a lawsuit, captioned Gonzalez v.

SEC original ↗Intellia Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

On May 15, 2025, a purported stockholder of the Company filed a stockholder derivative lawsuit, captioned Aiello v.

SEC original ↗Intellia Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026